Skip to main content

Table 2 Posterior probability of non-inferiority for FF/VI 100/25 mcg versus other relevant ICS/LABA* (full covariate model)

From: Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy

A: change from baseline FEV 1
Treatment Comparator Mean difference, L (95% CrI) Probability of non-inferiority margin (change from baseline)
    50 mL  
FF/VI 100/25 FP/SAL 500/50 0.023 (−0.002, 0.048) >99%  
FF/VI 100/25 BUD/FORM 400/12 0.027 (−0.007, 0.061) >99%  
B: annual rate of moderate/severe exacerbations    
Treatment Comparator Rate ratio (95% CrI) Probability of non-inferiority margin (event rate ratio)
    0.10 0.20
FF/VI 100/25 FP/SAL 500/50 0.925 (0.451, 1.734) 73% 80%
FF/VI 100/25 BUD/FORM 400/12 0.866 (0.396, 1.664) 77% 84%
C: change from baseline SGRQ Total score    
Treatment Comparator Mean difference, units (95% CrI) Probability of non-inferiority margin (units)
    2 3
FF/VI 100/25 FP/SAL 500/50 −1.321 (−3.955, 1.313) 99% >99%
FF/VI 100/25 BUD/FORM 400/12 −0.964 (−3.897, 1.970) 98% >99%
  1. Note: All stated nominal doses are mcg.
  2. BUD = budesonide, Crl = credible interval, FORM = formoterol, FEV1 = forced expiratory volume in one second, FF = fluticasone furoate, FP = fluticasone propionate, S = salmeterol, SGRQ = St George’s Respiratory Questionnaire, VI = vilanterol.
  3. *Other relevant ICS/LABA: FP/SAL 500/50 mcg and BUD/F 400/12 mcg.
  4. †For studies in which patients were required to have an explicit exacerbation history at entry.